PAX5 and acute myeloid leukemia: Of the cases of pDC-AML, we observed cyto-CD22 expression in 87.5% (7/8) of cases, CD19 expression in 75% (6/8), cyto-CD79a expression in 62.5% (5/8), CD20 in 12.5% (1/8), and PAX5 expression by IHC in 83.3% (5/6) of the available cases (Table 2 and Supplemental Figure S2).